TargetBeta
HLA-DQB1
major histocompatibility complex, class II, DQ beta 1 · also IDDM1, CELIAC1, HLA-DQB · Histocompatibility complex
1 program in company-led studies act on HLA-DQB1, from 1 company: 0 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule; the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| DONQ52 | Hoffmann-La Roche | phase 2 | 21 running | HLA-DQA1 | the company's pipeline |
Also acted on by the same programs
Conditions their studies are in
- Celiac Disease, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Jun 15, 2027DONQ52 · Hoffmann-La Roche · phase 2 · NCT07239336
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.